Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial
Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
STAT3h
Neomorph, AbbVie strike $1.64 billion deal
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
ncbiotech.org15h
Azzur serves NC biosciences with “Cleanrooms on Demand”
Azzur Cleanrooms on Demand (COD) has entered this acronym-laden environment to provide cleanroom and laboratory spaces for so-called GxP manufacturing support. Opened in May 2023, it’s a 75,000-square ...